uniQure (QURE) Highlights New Data from Phase I/II Clinical trial of AMT-060 Showing Successful Liver Transduction with AAV5 Vector
Tweet Send to a Friend
uniQure N.V. (NASDAQ: QURE) presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
